7 completed, 1 recruiting, 1 unknown. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 7, Recruiting 1, Unknown 1 |
Follow Cholera: new trials by email Literature Review of Cholera trials Research Report on Cholera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya Euvichol-S Oral Cholera Vaccine - Cholera Vaccination | Phase 4 | Recruiting | Albert B. Sabin Vaccine Institute | 1071 | 2025-10-31 | 2026-03-23 |
| Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines Oral typhoid fever vaccine, Oral cholera vaccine - Vaccine-Preventable Diseases, Typhoid Fever | Phase 4 | Completed | Helsinki University Central Hospital | 65 | 2023-10-25 | 2024-12-05 |
| Immune Response to a Delayed Second Dose of Oral Cholera Vaccine Delayed second dose of oral cholera vaccine, Euvichol-Plus, Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice - Cholera, Vibrio Cholerae Infection | Phase 4 | Unknown | Epicentre | 456 | 2022-07-20 | 2023-03-07 |
| Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Oral Cholera Vaccine, Adjusted Dose Oral Cholera Vaccine - Cholera, Vibrio Cholerae Infection | Phase 4 | Completed | Johns Hopkins Bloomberg School of Public Health | 120 | 2017-11-16 | 2021-04-05 |
| VAXCHORA Pediatric Study to Assess Safety and Immunogenicity VAXCHORA (Cholera Vaccine, Live, Oral), Placebo - Cholera (Disorder) | Phase 4 | Completed | Bavarian Nordic | 550 | 2017-07-21 | 2023-06-28 |
| A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell - Cholera | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 336 | 2014-03-01 | 2018-03-23 |
| Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Killed Bivalent (O1 and O139) whole cell oral cholera vaccine, Placebo - Vibrio Cholerae, Cholera | Phase 4 | Completed | International Vaccine Institute | 216 | 2012-12-01 | 2015-05-04 |
| Evaluation of a Boosting Regimen With Oral Cholera Vaccine Shanchol™, oral cholera vaccine, Shanchol™, killed, whole cell, bivalent, oral cholera vaccine, no intervention - Cholera | Phase 4 | Completed | Sachin Desai | 426 | 2012-12-01 | 2013-09-25 |
| A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children killed bivalent (O1 and O139)whole cell oral cholera vaccine - Vibrio Cholerae | Phase 4 | Completed | International Vaccine Institute | 200 | 2012-03-01 | 2014-06-17 |
Typhoid Fever (1) · Vaccine-Preventable Diseases (1)
Bacterial Infections (9) · Bacterial Infections and Mycoses (9) · Gram-Negative Bacterial Infections (9) · Infections (9) · Vibrio Infections (9) · Enterobacteriaceae Infections (1) · Salmonella Infections (1)
Cholera Vaccines (5) · shanchol (4) · Dukoral (1) · Ty21a typhoid vaccine (1) · Vaxchora (1)
International Vaccine Institute (2) · Albert B. Sabin Vaccine Institute (1) · Bavarian Nordic (1) · Epicentre (1) · Helsinki University Central Hospital (1) · Johns Hopkins Bloomberg School of Public Health (1) · Sachin Desai (1) · Sanofi Pasteur, a Sanofi Company (1)
India (2) · Ethiopia (1) · Finland (1) · Guinea (1) · Kenya (1) · Philippines (1) · United States (1) · Zambia (1)
Amanda K Debes, PhD (1) · Anu Kantele, MD, PhD (1) · Paul Andre de Lame, MD (1) · Suman Kanungo, MBBS (1) · Venkata R Mohan, M.D., MPH (1)
PMID 26078323, PMID 28910563, PMID 31211792, PMID 31769402, PMID 34217572